The use of the nickname 'Ketamine Queen' in connection to the woman charged in Matthew Perry's ketamine overdose case has sparked a legal debate. Jasveen Sangha, referred to as the 'Ketamine Queen' in court documents, faces multiple drug-related charges.
Sangha's legal team denies any connection between her and Perry, emphasizing that the rumors are baseless. The inclusion of the nickname in the indictment has raised concerns about potential jury prejudice.
The U.S. Attorney's Office accuses Sangha of providing ketamine to Perry through her middleman, Erik Fleming, and the actor's assistant, Kenneth Iwamasa. The fatal dose of ketamine allegedly led to Perry's death on Oct. 28.
The defense argues that the use of the nickname paints Sangha in a negative light and could bias jurors. Legal experts suggest that the nickname's inclusion may be admissible in court if Sangha embraced it or used it herself.
Sangha, Fleming, and Iwamasa allegedly attempted to cover up their involvement in Perry's death by deleting digital evidence and cleaning the scene. While Sangha maintains her innocence and is set to go to trial in March 2025, Fleming and Iwamasa have accepted plea agreements.
The legal community is divided on the appropriateness of using the 'Ketamine Queen' nickname in the case. Some argue that it could help establish Sangha's reputation in drug circles, while others view it as potentially prejudicial.
As the legal proceedings continue, the debate over the nickname's impact on the case's outcome remains a focal point. The trial in March 2025 will shed more light on the significance of the 'Ketamine Queen' moniker in the context of the charges against Sangha.
